Search results for "hematopoietic stem cell"

showing 10 items of 401 documents

Human γδ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias

2018

γδ T lymphocytes are potent effector cells, capable of efficiently killing tumor and leukemia cells. Their activation is mediated by γδ T-cell receptor (TCR) and by activating receptors shared with NK cells (e.g., NKG2D and DNAM-1). γδ T-cell triggering occurs upon interaction with specific ligands, including phosphoantigens (for Vγ9Vδ2 TCR), MICA-B and UL16 binding protein (for NKG2D), and PVR and Nectin-2 (for DNAM-1). They also respond to cytokines undergoing proliferation and release of cytokines/chemokines. Although at the genomic level γδ T-cells have the potential of an extraordinary TCR diversification, in tissues they display a restricted repertoire. Recent studies have identified …

lcsh:Immunologic diseases. Allergy0301 basic medicineαβ T-cellChemokineB-cell depletion; hematopoietic stem cells; HLA-haploidentical transplantation; receptors; αβ T-cell; γδ T-cellsReceptors Antigen T-Cell alpha-betaMini ReviewHLA-haploidentical transplantationImmunologyGenes MHC Class Ichemical and pharmacologic phenomenaMajor histocompatibility complexCD19Mice03 medical and health sciencesγδ T-cellsAntigenReceptorsMHC class ImedicineAnimalsHumansImmunology and AllergyIntraepithelial LymphocytesB-LymphocytesLeukemiaB-cell depletionbiologyT-cell receptorHematopoietic Stem Cell Transplantationmedicine.diseaseNKG2DKiller Cells NaturalLeukemia030104 developmental biologySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICACytomegalovirus InfectionsImmunologybiology.proteinlcsh:RC581-607Hematopoietic stem cellsFrontiers in Immunology
researchProduct

INFECTIOUS COMPLICATIONS AFTER UMBILICAL CORD-BLOOD TRANSPLANTATION FROM UNRELATED DONORS

2016

Umbilical cord-blood (UCB) is a well-recognized alternative source of stem cells for unrelated donor hematopoietic stem cell transplantation (HSCT). As compared with other stem cell sources from adult donors, it has the advantages of immediate availability of cells, absence of risk to the donor and reduced risk of graft-versus-host disease despite donor-recipient HLA disparity. However, the use of UCB is limited by the delayed post-transplant hematologic recovery due, at least in part, to the reduced number of hematopoietic cells in the graft and the delayed or incomplete immune reconstitution. As a result, severe infectious complications continue to be a leading cause of morbidity and mort…

lcsh:RC633-647.5Umbilical Cord Blood Transplantationbusiness.industryIncidence (epidemiology)medicine.medical_treatmentReview Articlelcsh:Diseases of the blood and blood-forming organsHematologyHuman leukocyte antigenDiseaseHematopoietic stem cell transplantation: umbilical cord-blood transplantation infectious bacterial fungal viral03 medical and health sciencesHaematopoiesisfluids and secretions0302 clinical medicineInfectious DiseasesImmune system030220 oncology & carcinogenesisImmunologymedicineStem cellbusiness030215 immunologyMediterranean Journal of Hematology and Infectious Diseases
researchProduct

Impact of Prophylactic CD8-Depleted Donor-Lymphocyte Infusions After Allogeneic Hematopoietic Stem Cell Transplantation and Alemtuzumab Mediated T-Ce…

2011

Abstract Abstract 4109 We have previously demonstrated that the application of CD8-depleted donor-lymphocyte infusions (DLI) is feasible after reduced-intensity conditioning and in vivo T-cell depletion by alemtuzumab. DLI overcome slow lymphocyte recovery associated with alemtuzumab-administration and improve anti-infectious immunity and reliably convert a decreasing T-cell chimerism (Meyer et al. Blood 2007 & BMT 2010). Here we provide clinical follow up data of 117 patients with different hematological diseases and a median observation time of 1 year (range, 1–86 months) post hematopoietic stem cell transplantation (HSCT). The majority of patients either suffered from an acute leukem…

medicine.medical_specialtyAcute leukemiabusiness.industrymedicine.medical_treatmentImmunologyContext (language use)Cell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseaseBiochemistryGastroenterologySurgeryTransplantationGraft-versus-host diseaseInternal medicinemedicineAlemtuzumabbusinessSurvival analysisMultiple myelomamedicine.drugBlood
researchProduct

Toxoplasmosis after hematopoietic stem transplantation. Report of a 5-year survey from the Infectious Diseases Working Party of the European Group fo…

2000

Toxoplasmosis after hematopoietic stem transplantation. Report of a 5-year survey from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

medicine.medical_specialtyBone marrow transplantPremedicationAntibodies ProtozoanBlood DonorsOpportunistic InfectionsImmunocompromised HostSeroepidemiologic StudiesInternal medicineTrimethoprim Sulfamethoxazole Drug CombinationEpidemiologymedicineAnimalsHumansTransplantation HomologousTransplantationMarrow transplantationbusiness.industryHematopoietic Stem Cell TransplantationHematologymedicine.diseaseToxoplasmosisTransplantationHaematopoiesissurgical procedures operativeImmunologybusinessToxoplasmaDisease transmissionToxoplasmosisBone Marrow Transplantation
researchProduct

Cationic lipide mediated transfer of c-abl and bcr antisense oligonucleotides to immature normal myeloid cells: Uptake, biological effects and modula…

1996

Uptake and biochemical and biological effects of antisense oligodeoxynucleotides (ODN) specific for c-abl and bcr genes were studied in normal immature myeloid cells. CD34-positive cells were purified by positive and negative selection and cultured in liquid culture for 7 days. These cells were then incubated with ODNs, either alone or in combination with cationic lipids. The uptake of ODNs was enhanced by the use of cationic lipids. In addition, very low concentrations of ODNs in combination with cationic lipids were capable of specifically inhibiting the expression of the c-abl gene. In contrast, no effects were seen on the expression of bcr. However, despite the effective blocking of c-a…

medicine.medical_specialtyCell Membrane PermeabilityChemical PhenomenaMolecular Sequence DataRibonuclease HAntigens CD34BiologyTransfectionPolymerase Chain ReactionCationsProto-Oncogene Proteinshemic and lymphatic diseasesInternal medicineGene expressionmedicineHumansCation Exchange ResinsRNA NeoplasmProto-Oncogene Proteins c-ablGeneCells CulturedOncogene ProteinsABLHematologyBase SequenceCell-Free SystemChemistry PhysicalCell growthCationic polymerizationbreakpoint cluster regionBiological Transporthemic and immune systemsHematologyGeneral MedicineOligonucleotides AntisenseProtein-Tyrosine Kinasesrespiratory systemHematopoietic Stem CellsLipidsMolecular biologyHaematopoiesisGene Expression RegulationDepression ChemicalLiposomesProto-Oncogene Proteins c-bcrAnnals of Hematology
researchProduct

A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood ‘high-risk’ acute lymphoblastic leukaemia:…

2002

The outcome of children with acute lymphoblastic leukaemia (ALL) and early relapse remains unsatisfactory. In January 1995, the AIEOP (Associazione Italiana di Oncologia ed Ematologia Pediatrica) group opened a trial for children with ALL in first isolated or combined bone marrow relapse defined at high risk according to the length of first remission and the immunophenotype. The treatment plan included the combination of a single high-dose idarubicin and high-dose cytarabine as induction therapy followed by an intensive consolidation and stem cell transplant (SCT). In total, 100 children from 16 Italian centres were enrolled; 80 out of the 99 evaluable patients (81%) achieved second complet…

medicine.medical_specialtyChemotherapybusiness.industrymedicine.drug_classmedicine.medical_treatmentHematologyHematopoietic stem cell transplantationmedicine.diseaseAntimetaboliteSurgerymedicine.anatomical_structureInternal medicineAcute lymphocytic leukemiaCytarabineMedicineIdarubicinBone marrowbusinessSurvival ratemedicine.drugBritish Journal of Haematology
researchProduct

Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the …

2018

Summary Cytomegalovirus is one of the most important infections to occur after allogeneic haematopoietic stem cell transplantation (HSCT), and an increasing number of reports indicate that cytomegalovirus is also a potentially important pathogen in patients treated with recently introduced drugs for hematological malignancies. Expert recommendations have been produced by the 2017 European Conference on Infections in Leukaemia (ECIL 7) after a review of the literature on the diagnosis and management of cytomegalovirus in patients after HSCT and in patients receiving other types of therapy for haematological malignancies. These recommendations cover diagnosis, preventive strategies such as pr…

medicine.medical_specialtyCongenital cytomegalovirus infectionCytomegalovirusAntiviral AgentsLetermovirInternal medicinemedicineHumansIn patientGanciclovirLeukemiabusiness.industryHematopoietic Stem Cell TransplantationMaribavirmedicine.diseaseTransplantationClinical trialHaematopoiesisInfectious DiseasesHematologic NeoplasmsCytomegalovirus InfectionsPractice Guidelines as TopicBenzimidazolesRibonucleosidesStem cellbusinessmedicine.drugThe Lancet. Infectious diseases
researchProduct

Consensus on performing skin biopsies, laboratory workup, evaluation of tissue samples and reporting of the results in patients with suspected cutane…

2014

Background Histopathological diagnosis including selection of lesions, the determination of the best point of time for biopsy and workup is not trivial in cutaneous graft-versus-host disease (GvHD). Objectives To develop interdisciplinary recommendations on performing, the laboratory work up and reporting of the results of skin biopsies in patients with suspected cutaneous GvHD. Methods A working group consisting of dermatopathologists, dermatologists, transplant-physicians and transplant-pathologists prepared recommendations for performing skin biopsies, laboratory workup and evaluation of tissue samples, and reporting of the results in patients with cutaneous GvHD. After achieving a conse…

medicine.medical_specialtyConsensusBiopsymedicine.medical_treatmentMedizinGraft vs Host DiseaseDermatologyDiseaseSkin Diseasesimmune system diseasesSurveys and QuestionnairesBiopsyHumansTransplantation HomologousMedicineIn patientSkinintegumentary systemmedicine.diagnostic_testbusiness.industryHistological TechniquesHematopoietic Stem Cell TransplantationImmunosuppressionCutaneous graft-versus-host diseaseDermatologyWork-upSurgeryTransplantationsurgical procedures operativeInfectious DiseasesAcute DiseaseChronic DiseaseSkin biopsybusiness
researchProduct

Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with acute lymphoblastic leukemi…

2014

Abstract Total-body-irradiation (TBI) based preparative regimens are considered as standard conditioning therapy for allogeneic stem cell transplantation (AHSC) in patients with acute lymphoblastic leukemia (ALL). Within a multi-center prospective phase II study we have investigated the toxicity and efficacy of a non-TBI-based regimen consisting of treosulfan, etoposide, and cyclophosphamide in patients with ALL. Inclusion criteria were complete remission, non-eligibility for TBI or patient’s wish to avoid TBI. Between July 2007 and August 2010, 50 patients with a median age of 46.5 years were enrolled at ten German centers. 74% of the patients were in 1. CR and 26% 2. or higher CR.The cond…

medicine.medical_specialtyCyclophosphamidebusiness.industrymedicine.medical_treatmentImmunologyPhases of clinical researchCell BiologyHematologyHematopoietic stem cell transplantationTreosulfanBiochemistrySurgeryTransplantationRegimenInternal medicinemedicineCumulative incidencebusinessEtoposidemedicine.drug
researchProduct

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTOHSCT) IN CLL: FIRST RESULTS OF AN EBMT RANDOMIZED TRIAL COMPARING AUTOTRANSPLANT VERSUS WAIT …

2010

Abstract Abstract 877 This phase-III randomized EBMT-intergroup trial studied the impact of a consolidating autoHSCT vs no consolidation for patients with CLL in Binet stage A progressive, B or C , in CR, nodular PR or VGPR after first or second line therapy. The primary objective was to show that autoHSCT increased the 5-year progression-free survival (PFS) by 30%. Although it had been calculated that 270 patients were to be randomized, the study was terminated by the steering committee in July 2007 due to poor accrual. Here we present a first analysis based on 69% of expected follow-up forms. Results: Between November 2001 and July 2007, 223 patients were enrolled (SFGM-TC/FCLLG n=98, MRC…

medicine.medical_specialtyDisease statusRandomizationbusiness.industrymedicine.medical_treatmentIncidence (epidemiology)ImmunologyCell BiologyHematologyHematopoietic stem cell transplantationBiochemistrySurgerylaw.inventionRandomized controlled triallawInternal medicinemedicineIn patientProgression-free survivalStage (cooking)business
researchProduct